Welcome to PsychiatryAI.com: [PubMed] - Psychiatry AI Latest

Liposomal Epigallocatechin-3-Gallate for the Treatment of Intestinal Dysbiosis in Children with Autism Spectrum Disorder: A Comprehensive Review

Evidence

Nutrients. 2023 Jul 24;15(14):3265. doi: 10.3390/nu15143265.

ABSTRACT

Autism Spectrum Disorder (ASD) is characterized by varying degrees of difficulty in social interaction and communication. These deficits are often associated with gastrointestinal symptoms, indicating alterations in both intestinal microbiota composition and metabolic activities. The intestinal microbiota influences the function and development of the nervous system. In individuals with ASD, there is an increase in bacterial genera such as Clostridium, as well as species involved in the synthesis of branched-chain amino acids (BCAA) like Prevotella copri. Conversely, decreased amounts of Akkermansia muciniphila and Bifidobacterium spp. are observed. Epigallocatechin-3-gallate (EGCG) is one of the polyphenols with the greatest beneficial activity on microbial growth, and its consumption is associated with reduced psychological distress. Therefore, the objective of this review is to analyze how EGCG and its metabolites can improve the microbial dysbiosis present in ASD and its impact on the pathology. The analysis reveals that EGCG inhibits the growth of pathogenic bacteria like Clostridium perfringens and Clostridium difficile. Moreover, it increases the abundance of Bifidobacterium spp. and Akkermansia spp. As a result, EGCG demonstrates efficacy in increasing the production of metabolites involved in maintaining epithelial integrity and improving brain function. This identifies EGCG as highly promising for complementary treatment in ASD.

PMID:37513683 | DOI:10.3390/nu15143265

Document this CPD Copy URL Button

Google

Google Keep Add to Google Keep

LinkedIn Share Share on Linkedin Share on Linkedin

Estimated reading time: 4 minute(s)

Latest: Psychiatryai.com #RAISR4D

Real-Time Evidence Search [Psychiatry]

Liposomal Epigallocatechin-3-Gallate for the Treatment of Intestinal Dysbiosis in Children with Autism Spectrum Disorder: A Comprehensive Review

🌐 90 Days

Evidence Blueprint

Liposomal Epigallocatechin-3-Gallate for the Treatment of Intestinal Dysbiosis in Children with Autism Spectrum Disorder: A Comprehensive Review

QR Code

☊ AI-Driven Related Evidence Nodes

(recent articles with at least 5 words in title)

Save Evidence Blueprint

Save as PDF

Liposomal Epigallocatechin-3-Gallate for the Treatment of Intestinal Dysbiosis in Children with Autism Spectrum Disorder: A Comprehensive Review

🌐 365 Days

close chatgpt icon
ChatGPT

Enter your request.